---
schema_version: "secwatch.filing_event.v1"
accession: "0001818382-22-000195"
form_type: "8-K"
ticker: "HUMA"
cik: "0001818382"
company_name: "Humacyte, Inc."
filed_at: "2022-12-12T23:59:59+00:00"
generated_at: "2026-06-21T06:17:48.383285+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.2
confidence: "high"
source: SEC EDGAR
---

# Humacyte amends bylaws to strengthen director nomination rules and align with Delaware law

## Summary
- Board approved amended bylaws effective Dec 8, 2022, adding universal proxy rule compliance requirements (Rule 14a-19).
- Stockholders nominating directors must state intent to solicit proxies and provide evidence of compliance upon request.
- Company may disregard proxies/votes if nominating stockholder fails to meet Rule 14a-19 requirements.
- Bylaws updated for Delaware law: clarify virtual meeting adjournment procedures, eliminate stockholder list inspection requirement.

## SEC filing metadata
- accession: 0001818382-22-000195
- form_type: 8-K
- ticker: HUMA
- cik: 0001818382
- company_name: Humacyte, Inc.
- filed_at: 2022-12-12T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.2
- confidence: high
- sec_items: 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1818382/000181838222000195/0001818382-22-000195-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1818382/000181838222000195/huma-20221208.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001818382-22-000195
- JSON: https://secwatch.observer/filing/0001818382-22-000195.json
- Plain text: https://secwatch.observer/filing/0001818382-22-000195.txt

## Key facts
- Governance Changes
  Humacyte, Inc.: The board of directors approved amended and restated bylaws, effective immediately (effective 2022-12-08).
  - Change: bylaw amendment
  - Effective: 2022-12-08
  source text: On December 8, 2022, the board of directors of Humacyte, Inc. (the “Company”) approved amended and restated by laws, which became effective the same day.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1818382/000181838222000195/0001818382-22-000195-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.